Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24615932 | 1.00 | RAB9A (0.41) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL12531865 | 0.82 | PIK3CD (0.47) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL17162628 | 0.82 | KMT2A (0.52) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL14378535 | 0.79 | SLC18A3 (0.42) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL6648293 | 0.78 | KMT2A (0.35) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL7604180 | 0.78 | KMT2A (0.39) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL18685310 | 0.78 | KMT2A (0.39) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL24481424 | 0.78 | KMT2A (0.39) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL13833151 | 0.78 | DRD2 (0.47) | MEN1KMT2ADRD2DRD3PIK3CD | |
| SCHEMBL8860654 | 0.78 | DRD2 (0.47) | MEN1KMT2ADRD2DRD3PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2024-05-02 | — | — | US | disclosed |
| EP-1349852-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | Sugen, Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055517-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | CUI JINGRONG (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140957-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | KRAS, NRAS, G3BP1 | RAB9A 67/4885MEN1 130/4885KMT2A 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.